{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T06:26:35Z","timestamp":1774765595046,"version":"3.50.1"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1097\/md.0000000000009672","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T18:42:00Z","timestamp":1516214520000},"page":"e9672","source":"Crossref","is-referenced-by-count":15,"title":["Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma"],"prefix":"10.1097","volume":"97","author":[{"given":"Rosa","family":"Falcone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michela","family":"Roberto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Filetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Anselmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Marchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-45-20210226","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.clinre.2015.09.008","article-title":"Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives","volume":"40","author":"Zaaimi","year":"2016","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"R2-45-20210226","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1200\/JCO.2008.19.7145","article-title":"Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of vater","volume":"27","author":"Overman","year":"2009","journal-title":"J Clin Oncol"},{"key":"R3-45-20210226","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/CAD.0b013e328350dd0d","article-title":"A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma","volume":"23","author":"Xiang","year":"2012","journal-title":"Anticancer Drugs"},{"key":"R4-45-20210226","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1634\/theoncologist.10-2-132","article-title":"Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma","volume":"10","author":"Gibson","year":"2005","journal-title":"Oncologist"},{"key":"R5-45-20210226","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1002\/cncr.30766","article-title":"North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma","volume":"123","author":"McWilliams","year":"2017","journal-title":"Cancer"},{"key":"R6-45-20210226","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/sj.bjc.6605449","article-title":"Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine","volume":"102","author":"Overman","year":"2010","journal-title":"Br J Cancer"},{"key":"R7-45-20210226","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/cncr.30445","article-title":"Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2 study","volume":"123","author":"Gulhati","year":"2017","journal-title":"Cancer"},{"key":"R8-45-20210226","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clcc.2016.04.013","article-title":"Evaluation of bevacizumab in advanced small bowel adenocarcinoma","volume":"16","author":"Aydin","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"R9-45-20210226","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00280-017-3371-0","article-title":"Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer","volume":"80","author":"Takayoshi","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"R10-45-20210226","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/sj.bjc.6605898","article-title":"Cetuximab in small bowel adenocarcinoma: a new friend?","volume":"103","author":"Santini","year":"2010","journal-title":"Br J Cancer"},{"key":"R11-45-20210226","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1136\/gut.2009.196428","article-title":"Molecular characterisation and cetuximab-based treatment in a patient with refractory small bowel adenocarcinoma","volume":"59","author":"De Dosso","year":"2010","journal-title":"Gut"},{"key":"R12-45-20210226","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1136\/gut.2008.153866","article-title":"Bevacizumab-based therapy for advanced small bowel adenocarcinoma","volume":"57","author":"Tsang","year":"2008","journal-title":"Gut"},{"key":"R13-45-20210226","first-page":"E1","article-title":"Complete response and prolonged disease-free survival in a patient with recurrent duodenal adenocarcinoma treated with bevacizumab plus FOLFOX6","volume":"5","author":"Nagaraj","year":"2014","journal-title":"J Gastrointest Oncol"},{"key":"R14-45-20210226","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clcc.2016.06.005","article-title":"Association between proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumors: a randomized phase II trial","volume":"15","author":"Marchetti","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"R15-45-20210226","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.dld.2016.08.126","article-title":"High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: a case series and the state of art","volume":"48","author":"Falcone","year":"2016","journal-title":"Dig Liver Dis"},{"key":"R16-45-20210226","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1002\/cncr.25614","article-title":"Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study","volume":"117","author":"Zaanan","year":"2011","journal-title":"Cancer"},{"key":"R17-45-20210226","doi-asserted-by":"crossref","first-page":"iv168","DOI":"10.1093\/annonc\/mdu333.3","article-title":"Phase II study of first-line mFOLFOX plus cetuximab (C) for 8 cycles followed by mFOLFOX plus C or single agent (S\/A) C as maintenance therapy in patients (P) with metastatic colorectal cancer (mCRC): The MACRO-2 trial (Spanish Cooperative Group for the Treatment of Digestive Tumors [TTD])","volume":"25","author":"Garc\u00eda Alfonso","year":"2014","journal-title":"Ann Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000009672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:53:02Z","timestamp":1620960782000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201801190-00045"}},"subtitle":["Case report and literature review"],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000009672","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]}}}